Please login to the form below

Not currently logged in
Email:
Password:

Astellas sells diabetes patents

Prosidion, a subsidiary of Astellas Pharma, has sold its patent estate relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes to Royalty Pharma for $609m

Prosidion, a subsidiary of Astellas Pharma, has sold its patent estate relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes to Royalty Pharma for $609m.

In July 2004, Prosidion acquired a portfolio of medical use patents related to the use of DPP-IV inhibitors for the treatment of type 2 diabetes. A number of non-exclusive licences to these patents have been granted to pharmaceutical companies around the world.

Royalty Pharma will be entitled to receive 100 per cent of royalty payments and milestones related to the DPP-IV asset. It will also take over administration of the DPP-IV patent estate currently owned by Prosidion.

Yoshihiko Hatanaka, president and chief executive of Astellas, said: "The sale of Prosidion's DPP-IV patent estate and royalty stream supports our strategic goal of maximising value for Astellas' shareholders. The sale of this large, passive, non-core financial asset will free up capital for reinvestment in strategic initiatives. We are pleased to have been able to work with Royalty Pharma in this important transaction."

Prosidion's assets include two drug candidates in development for diabetes and obesity, and research and development capabilities. Astellas will continue to review strategic alternatives for these assets. The range of alternatives that will be assessed could include minority investment or strategic alliance, a merger or sale of some or all of these assets.

Prosidion was acquired as part of Astellas' acquisition of OSI Pharmaceuticals in June 2010. The transaction is expected to close in July 2011.

30th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics